2-(2-Methylsulfanylpyrimidin-4-yl)-1-(3-trifluoromethylphenyl)ethanone | 200801-88-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(2-Methylsulfanylpyrimidin-4-yl)-1-(3-trifluoromethylphenyl)ethanone
• 英文别名: 2-<2-(methylthio)pyrimidin-4-yl>-1-<3-(trifluoromethyl)phenyl>ethanone；α-(2-methylthiopyrimidine-4-yl)-3-trifluromethylacetophenone；2-(2-methylthiopyrimidin-4-yl)-1-(3-trifluoromethylphenyl)ethanone；2-[2-(methylsulfanyl)pyrimidin-4-yl]-1-[3-(trifluoromethyl)phenyl]ethanone；2-(2-methylsulfanyl-pyrimidin-4-yl)-1-(3-trifluoromethyl-phenyl)-ethanone；2-[2-(Methylthio)pyrimidin-4-yl]-1-[3-(trifluoromethyl)phenyl]ethanone；2-(2-methylsulfanylpyrimidin-4-yl)-1-[3-(trifluoromethyl)phenyl]ethanone
• CAS: 200801-88-3
• 化学式: C₁₄H₁₁F₃N₂OS
• 分子量: 312.315
• InChiKey: DXWVQCGXUJJIBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  68.2
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-(2-Methylsulfanylpyrimidin-4-yl)-1-(3-trifluoromethylphenyl)ethanone 在 sodium tungstate 、 双氧水 、 sodium hydride 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 乙醇 、 二甲基亚砜 、 乙酸乙酯 、 甲苯 为溶剂， 反应 95.0h， 生成 3-(3-trifluoromethylphenyl)-4-(2-methylsulfonylpyrimidin-4-yl)-6-(N-carbobenzoxypiperidin-4-yl)pyridazine
  参考文献：
  名称：

  Pyridazine based inhibitors of p38 MAPK

  摘要：

  Trisubstituted pyridazines were synthesized and evaluated as in vitro inhibitors of p38 MAPK. The most active isomers were those possessing an aryl group alpha and a heteroaryl group beta relative to the nitrogen atom in the 2-position of the central pyridazine. Additionally, substitution in the 6-position of the central pyridazine with a variety of dialkylamino substituents afforded a set of inhibitors having good (p38 IC50 1-20 nM) in vitro activity. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00834-4
• 作为产物：
  描述：

  3-(三氟甲基)苯甲酰氯 在 三乙胺 、 lithium diisopropyl amide 作用下， 以 二氯甲烷 为溶剂， 反应 0.83h， 生成 2-(2-Methylsulfanylpyrimidin-4-yl)-1-(3-trifluoromethylphenyl)ethanone
  参考文献：
  名称：

  Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase

  摘要：

  Novel potent and selective diarylimidazole inhibitors of p38 MAP (mitogen-activated protein) kinase are described which have activity in both cell-based assays of tumor necrosis factor-alpha (TNF-alpha) release and an animal model of rheumatoid arthritis; The SAR leading to the development of selectivity against c-Raf and JNK2 alpha 1 kinases is presented, with key features being substitution of the 4-aryl ring with m-trifluoromethyl and substitution of the 5-heteroaryl ring with a a-amino substituent. Cell-based activity was significantly enhanced by incorporation of a 4-piperidinyl moiety at the 2-position of the imidazole which also enhanced aqueous solubility. In general, oral bioavailability of this class of compounds was found to be poor unless the imidazole was methylated on nitrogen. This work led to identification of 48, a potent (p38 MAP kinase inhibition IC50 0.24 nM) and selective p38 MAP kinase inhibitor which inhibits lipopolysaccharide-stimulated release of TNF-alpha from human blood with an IC50 2.2 nM, shows good oral bioavailability in rat and rhesus monkey, and demonstrates significant improvement in measures of disease progression in a rat adjuvant-induced arthritis model.

  DOI：

  10.1021/jm9805236

文献信息

• [EN] PYRAZOLOPYRIDINE DERIVATES<br/>[FR] DERIVES DE PYRAZOLOPYRIDINE
  申请人：URIACH Y COMPANIA S A J

  公开号：WO2004076450A1

  公开（公告）日：2004-09-10

  New compounds of formula (I) and the salts, solvates and prodrugs thereof, wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors.

  公式（I）的新化合物及其盐、溶剂合物和前药，其中各种取代基的含义如描述中所披露的。这些化合物可用作p38激酶抑制剂。
• [EN] MODULATORS OF HCV REPLICATION<br/>[FR] MODULATEURS DE LA REPLICATION DU VHC
  申请人：ANGELETTI P IST RICHERCHE BIO

  公开号：WO2006021449A1

  公开（公告）日：2006-03-02

  The present invention is directed to the use of certain 2,4,5-trisubstituted imidazole derivatives in modulating the replication of Hepatitis C virus RNA and/or virus production in cells.

  本发明涉及在调节丙型肝炎病毒RNA的复制和/或细胞中病毒产生中使用某些2,4,5-三取代咪唑衍生物。
• Substituted imidazoles having cytokine inhibitory activity
  申请人：Merck & Co., Inc.

  公开号：US05859041A1

  公开（公告）日：1999-01-12

  Compounds represented by formula I: ##STR1## are disclosed. .sup.AR represents an aromatic group containing 6-10 atoms; and ##STR2## represents a 4 to 10 membered non-aromatic heterocycle containing at least one N atom, and optionally containing 1-2 additional N atoms and 0-1 O or S atom. A pharmaceutical composition is also included. Methods of treating cancer and cytokine mediated diseases are also included.

  公式I代表的化合物被披露。.sup.AR代表含有6-10个原子的芳香族基团；而##STR2##代表含有至少一个N原子的4至10个成员非芳香族杂环，并且可选地含有1-2个额外的N原子和0-1个O或S原子。还包括一种药物组合物。还包括治疗癌症和细胞因子介导疾病的方法。
• Compounds having cytokine inhibitory activity
  申请人：Merck & Co., Inc.

  公开号：US06350744B1

  公开（公告）日：2002-02-26

  There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.

  公开了化合物的结构式（I）及其药学上可接受的盐，其对治疗细胞因子介导的疾病如关节炎具有实用性。
• Pyrazolopyridine derivates
  申请人：Almansa Rosales Carmen

  公开号：US20060167040A1

  公开（公告）日：2006-07-27

  New compounds of formula (I) and the salts, solvates and prodrugs thereof, wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors.

  新化合物的公式为（I），以及其盐，溶剂合物和前药，其中各种取代基的含义如描述所示。这些化合物可用作p38激酶抑制剂。